| Drug General Information |
| Drug ID |
D02IJP
|
| Former ID |
DIB002771
|
| Drug Name |
CLX-0900
|
| Synonyms |
CLX-0900E
|
| Indication |
Hyperlipidaemia [ICD9: 272.0-272.4; ICD10:E78]
|
Terminated |
[1]
|
|---|
| Company |
Calyx Therapeutics Inc
|
| Target and Pathway |
| Target(s) |
Insulin receptor |
Target Info |
Modulator |
[2]
|
|---|
|
KEGG Pathway
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
cGMP-PKG signaling pathway
|
|
HIF-1 signaling pathway
|
|
FoxO signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
AMPK signaling pathway
|
|
Adherens junction
|
|
Insulin signaling pathway
|
|
Ovarian steroidogenesis
|
|
Type II diabetes mellitus
|
|
Non-alcoholic fatty liver disease (NAFLD)
|
|
Aldosterone-regulated sodium reabsorption
|
|
NetPath Pathway
|
TGF_beta_Receptor Signaling Pathway
|
|
PANTHER Pathway
|
Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade
|
|
Insulin/IGF pathway-protein kinase B signaling cascade
|
|
PI3 kinase pathway
|
|
Pathway Interaction Database
|
Insulin Pathway
|
|
Signaling events mediated by PTP1B
|
|
Signaling events mediated by TCPTP
|
|
Insulin-mediated glucose transport
|
|
PathWhiz Pathway
|
Insulin Signalling
|
|
Leucine Stimulation on Insulin Signaling
|
|
Reactome
|
IRS activation
|
|
Signal attenuation
|
|
Insulin receptor signalling cascade
|
|
Insulin receptor recycling
|
|
WikiPathways
|
DNA Damage Response (only ATM dependent)
|
|
Insulin Signaling
|
|
Nanoparticle triggered autophagic cell death
|
|
AGE/RAGE pathway
|
|
Signaling by Insulin receptor
|
|
Folate Metabolism
|
|
Type II diabetes mellitus
|
|
Vitamin B12 Metabolism
|
|
Selenium Micronutrient Network
|
|
AMPK Signaling
|
| References |
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013573) |
|---|
| REF 2 | CLX-0901 (Calyx Therapeutics). Curr Opin Investig Drugs. 2001 May;2(5):650-3. |
|---|
